These compounds aren't cobwebs—they're anchors.
For generations, the molecular machinery of human inheritance has held a quiet debate within itself — are the chemical marks on silenced genes merely the residue of silence, or its cause? Researchers at UNSW Sydney have now answered that question, and in doing so, have opened a gentler path through one of medicine's most persistent dilemmas. By learning to lift the chemical anchors that keep healing genes dormant, scientists may soon offer people with sickle cell disease a treatment that works with the body's own grammar rather than rewriting it by force.
- A decades-long scientific dispute about whether methyl tags on DNA cause gene silencing or merely accompany it has been resolved — they are the lock, not just the shadow of one.
- Traditional CRISPR gene therapy cuts DNA strands to correct mutations, but that cutting carries a genuine cancer risk — a troubling gamble for patients already managing a lifelong disease.
- The new epigenetic approach sidesteps the scalpel entirely, using a modified CRISPR system to chemically strip silencing tags from dormant genes, coaxing them back to life without breaking the genome.
- The target is fetal globin — a gene that does the work of healthy blood in the womb but goes quiet after birth — which could compensate for the faulty adult gene driving sickle cell disease.
- Laboratory work on human cells is complete; animal trials are expected within years, with a treatment pathway that would edit a patient's own stem cells and return them to the bone marrow.
- The technology's reach may extend well beyond sickle cell disease, with researchers eyeing other genetic conditions and even agricultural applications as the next frontier.
For decades, scientists have disagreed about what chemical tags on DNA actually do — whether they are passive markers left behind when genes go quiet, or the active force keeping them silent. A team at UNSW Sydney has now settled the argument. In work published in Nature Communications, they removed methyl groups from silenced genes and watched them reactivate. Then they restored the tags, and the genes went dark again. The marks are not residue. They are the mechanism.
The finding matters most for what it makes possible. Traditional CRISPR therapy corrects genetic faults by cutting DNA — a powerful but dangerous approach that can trigger cancer. For patients with sickle cell disease, a condition that deforms red blood cells and brings chronic pain, organ damage, and shortened life, that risk has always shadowed the promise. The new method, epigenetic editing, never cuts. Instead, it delivers enzymes that strip methyl groups from specific genes, lifting the molecular brakes without touching the underlying code.
The researchers' target is fetal globin, a gene that carries oxygen-rich blood through the womb but normally shuts down after birth. In sickle cell patients, the adult globin gene that replaces it is faulty. The strategy is to reawaken the fetal version — to bring dormant machinery back online to compensate for what is broken. The work, conducted in collaboration with St Jude Children's Research Hospital, has so far been limited to human cells in the laboratory.
The clinical path forward involves collecting blood stem cells from a patient, editing them to remove the silencing tags from the fetal globin gene, and returning them to the bone marrow to produce healthier blood. Lead researcher Professor Merlin Crossley notes that this study is only the beginning — the same platform could be used to make other chemical modifications to gene output, and may eventually find applications in agriculture as well. What began as a fundamental question about how DNA works has become a blueprint for a safer kind of medicine, one that reads the genome's own language rather than overwriting it.
For decades, scientists have argued about what chemical tags on DNA actually do. Are they just junk that accumulates where genes have been switched off—genetic cobwebs, essentially—or are they the active force that keeps those genes silent in the first place? A team at UNSW Sydney has now settled the question decisively. In work published in Nature Communications, they removed methyl groups from silenced genes and watched them turn back on. Then they added the methyl groups back, and the genes switched off again. The tags are not cobwebs. They are anchors.
This discovery matters because it opens a new path to treating genetic diseases without the risks that have haunted gene therapy for years. Traditional CRISPR technology works by cutting DNA strands—finding faulty genes and either removing them or correcting the letters in the genetic code. But cutting DNA carries a real danger: it can trigger cancer. For someone with a lifelong disease like sickle cell, that trade-off has always been troubling. The new approach, called epigenetic editing, avoids cutting altogether. Instead, it uses a modified CRISPR system to deliver enzymes that strip methyl groups off DNA, essentially lifting the brakes on genes that have been silenced.
Sickle cell disease is a genetic mutation that warps the shape and function of red blood cells, leading to chronic pain, organ damage, and a shortened lifespan. The researchers believe epigenetic editing could offer a workaround. In the womb, a gene called fetal globin does the work of delivering oxygen-rich blood to a developing fetus. After birth, that gene normally shuts down and an adult globin gene takes over. But in people with sickle cell disease, the adult version is faulty. The idea is to reactivate the fetal globin gene—to get those training wheels working again—so it can compensate for the broken adult version.
The research was conducted in collaboration with St Jude Children's Research Hospital in Memphis and has so far been limited to laboratory work on human cells in test tubes. But the path forward is clear. In a few years, once animal testing and clinical trials are complete, the treatment would work like this: doctors would collect blood stem cells from a patient, use epigenetic editing to remove the methyl tags from the fetal globin gene in those cells, then return the edited cells to the patient's bone marrow. There, they would settle in and begin producing better-functioning blood cells.
Professor Merlin Crossley, the study's lead author and UNSW's Deputy Vice-Chancellor for Academic Quality, emphasizes that this is just the beginning. The team has shown it is now possible to target specific molecules to individual genes. They removed and added methyl groups in this study, but other chemical modifications could be made to alter gene output for therapeutic purposes—and potentially for agriculture as well. The researchers plan to test their approach in animal models next and to explore other CRISPR-related tools. What started as a fundamental question about how DNA actually works has become a blueprint for a safer kind of gene therapy, one that works with the genome's natural chemistry rather than against it.
Citações Notáveis
If you brush the cobwebs off, the gene comes on. And when we added the methyl groups back to the genes, they turned off again.— Professor Merlin Crossley, UNSW
Epigenetic editing allows us to boost gene expression without modifying the DNA sequence, with reduced risk of unintended negative effects compared to earlier CRISPR generations.— Professor Kate Quinlan, study co-author
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that methyl groups actually silence genes rather than just being correlated with silencing?
Because it changes what you can do. If they were just junk, you'd have to cut the DNA to fix the problem. But if they're the actual cause of silencing, you can simply remove them—no cutting, no cancer risk.
So this is safer than earlier CRISPR approaches?
Much safer. First-generation CRISPR cut DNA strands. Second-generation corrected individual letters. Both involved making cuts, which can trigger cancer. This doesn't cut at all. It just removes the chemical brake.
How does the fetal globin gene become a treatment for sickle cell?
In the womb, fetal globin delivers oxygen to the developing fetus. After birth, it normally shuts down and adult globin takes over. But in sickle cell patients, the adult version is broken. If you reactivate the fetal version, it can do the job the adult version can't.
Is this ready for patients now?
Not yet. Everything so far has been in test tubes. They need to test it in animals first, then run clinical trials. That's probably years away. But the science is solid.
Could this work for other diseases besides sickle cell?
That's the real promise. Any genetic disease where you need to turn a gene on or off by changing methyl groups could potentially be treated this way. The researchers see this as the beginning of something much larger.
What's the biggest risk with this approach?
Honestly, it's still early. But the advantage is you're not cutting DNA, so you're avoiding the mutation risk that comes with traditional gene therapy. You're working with the cell's own chemistry.